Affiliation:
1. Unité Traumatologie de Guerre, Institut de Recherche Biomédicale Des Armées Brétigny Sur Orge France
2. Hôpital D'instruction Des Armées Percy Clamart France
3. Service Innovation, Recherche et Développement, Centre de Transfusion Sanguine des Armées Clamart France
Abstract
AbstractBackgroundHemorrhagic shock is well documented as a leading cause of preventable fatalities among military casualties. During military operations plasma can be transfused while waiting for whole blood. This study was conducted to assess the safety and efficacy of two new freeze‐dried plasma formulations in a porcine model of traumatic hemorrhagic shock.Study Design and MethodsIn the face of species‐specific transfusion, transfusible blood products were derived from porcine sources. The efficacy of three lyophilized plasma (LP) formulations was evaluated: lyophilized plasma (LP), concentrated lyophilized plasma (CLP), and platelet‐rich concentrated lyophilized plasma (PCLP). Pigs were subjected to multi‐trauma and hemorrhagic shock. Ninety minutes post‐shock induction, the animals were treated with one of the three lyophilized products. Monitoring included systolic blood pressure and cardiac output. Point‐of‐care and laboratory diagnostic tests were used to assess renal function, real‐time hemostasis (ROTEM), and coagulation. Histological examinations of kidney, lung, and muscle tissues were conducted 4 h after shock induction.ResultsCLP and PCLP significantly improved systolic blood pressure and cardiac output and positively influenced base excess, creatinine, various ROTEM, and coagulation markers compared with standard LP without histologic modification. No adverse effect was associated with the transfusion of any of the plasma products throughout the experimental procedures.ConclusionBoth CLP and PCLP exhibit promising therapeutic potential for managing hemorrhagic shock in scenario where whole blood supplies are limited. However, the distinct physiological and coagulation characteristics of the swine model necessitate further investigation using humanized preclinical models to fully understand their clinical applicability and constraints.